期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗复发或难控型外周T细胞淋巴瘤新药——贝林司他 被引量：2

下载PDF
导出
摘要 贝林司他(belinostat)是一种组蛋白去乙酰化酶(HDAC)抑制药,可致乙酰化组蛋白和其他蛋白积蓄,诱导细胞周期停止和(或)部分转化细胞的凋亡,从而达到治疗外周T细胞淋巴瘤(PTCL)的目的。该文综述贝林司他的作用机制、药效学、药动学、临床试验及临床应用等,供临床应用参考。
作者 赵倩 屈慧新 史慧静 王彩霞
机构地区 石药集团中奇制药技术(石家庄)有限公司
出处 《医药导报》 CAS 2016年第5期551-554,共4页 Herald of Medicine
关键词 贝林司他 组蛋白去乙酰化酶抑制药 外周T细胞淋巴瘤
分类号 R979.1 [医药卫生—药品] R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1王学文,李锋.外周T细胞淋巴瘤的研究进展[J].现代肿瘤医学,2009,17(6):1173-1178. 被引量：10
  • 2Center for Drug Evaluation and Research Application Num-ber .206256Orig1s000 PHARMACOLOGY REVIEW(S)[EB/OL].[2014-07-03]..
  • 3KHAN N,JEFFERS M,KUMAR S, et al.Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors[J].Biochem J,2008,409(2):581-589.
  • 4PLUMB A,FINN P W,WILLIAMS R J,et al.Pharmaco-dynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101[J].Mol Cancer Ther,2003,2(8):721-728.
  • 5QIAN X,LAROCHELLE W J,ARA G,et al.Activity of PXD101,a histone deacetylase inhibitor in preclinical ovarian cancer studies[J].Mol Cancer Ther,2006,5(8):2086-2095.
  • 6FDA.Lable[EB/OL].[2014-07-03]..
  • 7GIMSING P,HANSEN M.A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia[J].Eur J Haematol,2008,81(3):170-176.
  • 8FOSS F,ADVANI R, DUVIC M,et al.A phase II trial of Belinostat(PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma[J].Br J Haematol,2015,168(6):811-819.
  • 9Center for Drug Evaluation and Research Application Num-ber .206256Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)[EB/OL].[2014-07-03]..
  • 10MACKAY H J, HIRTE H,COLGAN T,et al.Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary(LMP) ovarian tumors[J].Eur J Cancer,2010,46(9):1573-1579.

二级参考文献35

  • 1The Non-Hodgkin's Lymphoma Classification Project.A clinical evaluation of the International Lymphoma Study Group classication of non-Hodgkin's lymphoma[J].Blood,1997,89(11):3909-3918.
  • 2Vose JM.International Peripheral T-cell Lymphoma(PTCL)Clinical and Pathologic Review Project:poor outcome by prognostic indices and lack of efficacy with anthracyclines[J].Blood,2005,1006(11):239.
  • 3Rudiger T,Geissinger E,Muller-Hermelink HK.Normal counterparts' of nodal peripheral T-cell lymphoma[J].Hematol Oncol,2006,24(4):175-180.
  • 4Delves PJ,Roitt IM.The immune system.Second of two parts[J].N Engl J Med,2000,343(2):108-117.
  • 5Delves PJ,Roitt IM.The immune system.First of two parts[J].N Engl J Med,2000,343(1):37-49.
  • 6Stein H,Foss HD,Durkop H,et al.CD30(+)anaplastic large cell lymphoma:a review of its histopathologic,genetic,and clinical features[J].Blood,2000,97(12):3681-3695.
  • 7Chen CY,Yao M,Tang JL,et al.Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan:with special reference to T-cell lymphoma[J].Ann Oncol,2004,15(7):1091-1096.
  • 8Martinez-Delgado B,Cuadros M,Honrado E,et al.Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas[J].Leukemia,2005,19(12):2254-2263.
  • 9Ralfkiaer E,Muller-Hermelink HK,Jaffe ES.Peripheral T-cell lymphoma,unspecified[A].Jaffe ES,Harris NL,Stein H,et al.World Health Organization classification of tumours.Pathology and genetics of tumours of haematopoietic and lymphoid tissues[M].Lyon:IARC Press,2001:227-229.
  • 10Armitage JO,Cavalli F,Zucca E,eds.Text atlas of lymphomas(revised edition)[M].London:Martin Dunitz,2002:30-43.

共引文献9

同被引文献8

引证文献2

二级引证文献2

医药导报
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部